000048306 001__ 48306
000048306 005__ 20210121114527.0
000048306 0247_ $$2doi$$a10.3389/fmicb.2015.00684
000048306 0248_ $$2sideral$$a91648
000048306 037__ $$aART-2015-91648
000048306 041__ $$aeng
000048306 100__ $$aRufián, J.S.
000048306 245__ $$aAuto-acetylation on K289 is not essential for HopZ1a-mediated plant defense suppression
000048306 260__ $$c2015
000048306 5060_ $$aAccess copy available to the general public$$fUnrestricted
000048306 5203_ $$aThe Pseudomonas syringae type III-secreted effector HopZ1a is a member of the HopZ/YopJ superfamily of effectors that triggers immunity in Arabidopsis. We have previously shown that HopZ1a suppresses both local effector-triggered immunity (ETI)] and systemic immunity systemic acquired resistance (SAR)] triggered by the heterologous effector AvrRpt2. HopZ1a has been shown to possess acetyltransferase activity, and this activity is essential to trigger immunity in Arabidopsis. HopZ1a acetyltransferase activity has been reported to require the auto-acetylation of the effector on a specific lysine (K289) residue. In this paper we analyze the relevance of autoacetylation of lysine residue 289 in HopZ1a ability to suppress plant defenses, and on the light of the results obtained, we also revise its relevance for HopZ1a avirulence activity. Our results indicate that, while the HopZ1aK289R mutant is impaired to some degree in its virulence and avirulence activities, is by no means phenotypically equivalent to the catalytically inactive HopZ1aC216A, since it is still able to trigger a defense response that induces detectable macroscopic HR and effectively protects Arabidopsis from infection, reducing growth of P. syringae within the plant. We also present evidence that the HopZ1aK289R mutant still displays virulence activities, partially suppressing both ETI and SAR.
000048306 536__ $$9info:eu-repo/grantAgreement/ES/MICINN/AGL2010-22287-C02-2$$9info:eu-repo/grantAgreement/ES/MICINN/BIO2009-11516$$9info:eu-repo/grantAgreement/ES/MINECO/BIO2012-35641
000048306 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000048306 590__ $$a4.165$$b2015
000048306 591__ $$aMICROBIOLOGY$$b23 / 123 = 0.187$$c2015$$dQ1$$eT1
000048306 592__ $$a1.869$$b2015
000048306 593__ $$aMicrobiology (medical)$$c2015$$dQ1
000048306 593__ $$aMicrobiology$$c2015$$dQ1
000048306 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000048306 700__ $$0(orcid)0000-0002-0111-4697$$aLucía, A.$$uUniversidad de Zaragoza
000048306 700__ $$aMacho, A.P.
000048306 700__ $$aOrozco-Navarrete, B.
000048306 700__ $$aArroyo-Mateos, M.
000048306 700__ $$aBejarano, E.R.
000048306 700__ $$aBeuzón, C.R.
000048306 700__ $$aRuiz-Albert, J.
000048306 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000048306 773__ $$g6 (2015), 684 [12 pp]$$pFront. microbiol.$$tFRONTIERS IN MICROBIOLOGY$$x1664-302X
000048306 8564_ $$s1431168$$uhttps://zaguan.unizar.es/record/48306/files/texto_completo.pdf$$yVersión publicada
000048306 8564_ $$s102378$$uhttps://zaguan.unizar.es/record/48306/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000048306 909CO $$ooai:zaguan.unizar.es:48306$$particulos$$pdriver
000048306 951__ $$a2021-01-21-11:07:26
000048306 980__ $$aARTICLE